Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

i-care pharma distributors pty ltd - ocriplasmin -

Европска Унија - Енглески - EMA (European Medicines Agency)

novartis europharm limited - fingolimod hydrochloride  - multiple sclerosis - immunosuppressants - gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).orpatients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Европска Унија - Енглески - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ophthalmologicals - visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (amd) with predominantly classic subfoveal choroidal neovascularisation (cnv) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 1.65 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (amd),- the treatment of visual impairment due to diabetic macular oedema (dme),- the treatment of proliferative diabetic retinopathy (pdr),- the treatment of visual impairment due to choroidal neovascularisation.,- the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo)

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 2.3 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,? the treatment of neovascular (wet) age-related macular degeneration (amd), ? the treatment of visual impairment due to diabetic macular oedema (dme), ? treatment of proliferative diabetic retinopathy (pdr), ? the treatment of visual impairment due to choroidal neovascularisation, ? the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm), ? the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).,lucentis is indicated in preterm infants for:,? the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - nepafenac, quantity: 3 mg/ml - eye drops, suspension - excipient ingredients: carbomer 974p; carmellose sodium; benzalkonium chloride; boric acid; sodium hydroxide; hydrochloric acid; sodium chloride; propylene glycol; guar galactomannan; purified water; disodium edetate - ilevro is indicated for the:,- prevention and treatment of postoperative pain and inflammation associated with cataract surgery,- reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non proliferative diabetic retinopathy.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - faricimab 120 mg/ml - solution for injection - 120 mg/ml - active: faricimab 120 mg/ml excipient: acetic acid histidine methionine polysorbate 20 sodium chloride sucrose water for injection - vabysmo is indicated for the treatment of: · neovascular (wet) age-related macular degeneration (namd)

Европска Унија - Енглески - EMA (European Medicines Agency)

pharmaswiss ceska republika s.r.o - pegaptanib - wet macular degeneration - ophthalmologicals - macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (amd).

Сингапур - Енглески - HSA (Health Sciences Authority)

alcon pte ltd - ophthalmology - the grieshaber™ aspheric macular lens dsp is a sterile and single-use device intended to be used for visualization of the fundus in vitreoretinal surgery. the grieshaber™ aspheric macular lens dsp is designed as a self- retaining contact lens to allow hands-free operation.

Канада - Енглески - Health Canada

helena rubinstein canada - titanium dioxide - cream - 3.1g - titanium dioxide 3.1g - sunscreen agents